Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03861793
Title A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Alkermes, Inc.

Advanced Solid Tumor


ALKS 4230 + Pembrolizumab

ALKS 4230

Age Groups: adult | senior
Covered Countries USA | ESP | CAN

No variant requirements are available.